Full Press Release Details
Ocuphire to be Featured in Cantor Fitzgerald Fireside Chat with Equity Research Analyst Kristen Kluska.
IRD
Ocuphire to be Featured in Cantor Fitzgerald Fireside Chat with Equity Research Analyst Kristen Kluska
Key Takeaway: Ocuphire to be Featured in Cantor Fitzgerald Fireside Chat with Equity Research Analyst Kristen Kluska
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+140%
120-day peak, hindsight
Typical move
6.3%
average across 11 past catalysts
Cash runway
~22 mo
Low dilution risk
Lead asset
APX3330
Phase 2 · Diabetic Retinopathy